Form 4: Sana Biotechnology Director Receives Stock Option Grant

Director Hans Edgar Bishop was granted 90,000 stock options in Sana Biotechnology, Inc. as part of standard equity compensation.

Summary

• Director Hans Edgar Bishop received a grant of 90,000 stock options for Sana Biotechnology, Inc. (SANA) common stock.
• The options have an exercise price of $2.96 per share.
• The grant date for the transaction was June 4, 2026.
• The options are scheduled to vest in full on the earlier of June 4, 2027, or immediately prior to the 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $2.96 exercise price.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation packages for mid-cap biotechnology firms.
• The one-year cliff vesting schedule is a common practice for director equity awards in the life sciences industry.

Stakeholder Impact

• Shareholders may experience minor dilution if the options are exercised in the future.

Next Steps

• Vesting of options on June 4, 2027, or the 2027 annual meeting of stockholders.

Key Dates

Keywords

Sana Biotechnology, SANA, Stock Options, Director Compensation, Insider Transaction, Form 4